Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma. All three abstracts were presented at this year’s virtual ASCO.
Ziopharm will present updated clinical data from its Phase 1/2 controlled IL-12 program. Data will show clinical results of its IL-12 gene therapy, Ad+V, as a monotherapy and in combination with nivolumab for the treatment of recurrent glioblastoma (rGBM). Phase 1 data from this program have shown that treatment with Ad+V can double the median overall survival of patients with rGBM.